Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Stephen Evans-Freke | ADCT ADC Therapeutics SA | 13D/A | 2.7% | Apr 23, 2024 | 2y |
| EMINENCE CAPITAL, LP | ASH Ashland Inc. | 13D/A | 6.4% | Apr 23, 2024 | 2y |
| BW Group Limited | DHT DHT Holdings, Inc. | 13D/A | 14.9% | Apr 23, 2024 | 2y |
| BROWNING WEST LP | GIL Gildan Activewear Inc. | 13D/A | 5% | Apr 23, 2024 | 2y |
| Fairmount Funds Management LLC | SYRE Spyre Therapeutics, Inc. | 13D/A | 11.17% | Apr 23, 2024 | 2y |
| Fund 1 Investments, LLC | CTRN Citi Trends Inc | 13D/A | 22% | Apr 23, 2024 | 2y |
| Randa Duncan Williams | EPD Enterprise Products Partners L.P. | 13D/A | 32.3% | Apr 23, 2024 | 2y |
| Charles W. Riley, Jr., solely in his capacity as the successor trustee of the Everett W. Nordstrom Trust fbo AEG created under the will of Everett W. Nordstrom dated April 1, 1971, and as a successor co-trustee of the Frances W. Nordstrom Trust fbo BAN created under the will of Frances W. Nordstrom dated April 4, 1984. | JWN Nordstrom, Inc. | 13D | 7.62% | Apr 22, 2024 | 2y |
| Joseph Reda | GWAV Greenwave Technology Solutions, Inc. | 13G/A | 5.68% | Apr 22, 2024 | 2y |
| WOLVERINE ASSET MANAGEMENT LLC | DIST Distoken Acquisition Corporation Ordinary Shares | 13G/A | 4.57% | Apr 17, 2024 | 2y |
| Millennium Management LLC | MYGN Myriad Genetics Inc | 13G | 4.97% | Apr 17, 2024 | 2y |
| Paresh Patel | HCI HCI Group, Inc. | 13D/A | 14.77% | Apr 17, 2024 | 2y |
| Bain Capital Life Sciences Opportunities III, LP | IPSC Century Therapeutics, Inc. | 13G | 6.6% | Apr 15, 2024 | 2y |
| FiSai Fund I HoldCo Limited Partnership | AYRWF Ayr Wellness Inc. | 13G | 8.4% | Apr 15, 2024 | 2y |
| China International Capital Corporation Limited | UCL uCloudlink Group Inc. | 13G | 7.79% | Apr 15, 2024 | 2y |
| RA CAPITAL MANAGEMENT, L.P. | TARA Protara Therapeutics, Inc. | 13G | 9.99% | Apr 10, 2024 | 2y |
| Rosalind Advisors, Inc. | MDWD MediWound Ltd. | 13G/A | 6.92% | Mar 31, 2024 | 2y |
| Rosalind Advisors, Inc. | SPRB Spruce Biosciences, Inc. | 13G/A | 3.67% | Mar 31, 2024 | 2y |
| Rosalind Advisors, Inc. | CLRB Cellectar Biosciences, Inc. | 13G/A | 9.9% | Mar 31, 2024 | 2y |
| Rosalind Advisors, Inc. | NSPR InspireMD, Inc. | 13G/A | 4.2% | Mar 31, 2024 | 2y |
| Rosalind Advisors, Inc. | TRVI Trevi Therapeutics, Inc. | 13G/A | 1.34% | Mar 31, 2024 | 2y |
| Rosalind Advisors, Inc. | MYO Myomo, Inc. | 13G/A | 9.9% | Mar 31, 2024 | 2y |
| Wayne W. Boos | SLNH Soluna Holdings, Inc | 13D/A | 5.63% | Mar 31, 2024 | 2y |
| JEFF TOGHRAIE | AXIL Axil Brands, Inc. | 13D/A | 50.6% | Apr 22, 2024 | 2y |
| Saba Capital Management, L.P. | AFB Alliancebernstein National Municipal Income Fund | 13D/A | 9.24% | Apr 22, 2024 | 2y |
| Klaus Umek | CRTO Criteo S.A. | 13D/A | 7.76% | Apr 22, 2024 | 2y |
| New Enterprise Associates 17, L.P. | KRRO Korro Bio, Inc. | 13D/A | 11.8% | Apr 22, 2024 | 2y |
| MILLENNIUM MANAGEMENT LLC | VERU Veru Inc. | 13G | 5.2% | Apr 18, 2024 | 2y |
| Deerfield Management Company, L.P. | CGEM Cullinan Therapeutics, Inc. | 13G | 5.71% | Apr 18, 2024 | 2y |
| Scott Kapnick | MDIA Mediaco Holding Inc. | 13D | 18.4% | Apr 17, 2024 | 2y |
| Samuel Wu | OIO OIO Group | 13D | 43.48% | Apr 3, 2024 | 2y |
| Fosun International Ltd | AMRX Amneal Pharmaceuticals, Inc. | 13G/A | 3% | Mar 31, 2024 | 2y |
| McBey Robert G | ATCH AtlasClear Holdings, Inc. | 13D | 7.7% | Feb 9, 2024 | 2y |
| Relative Value Partners Group, LLC | CCIF Carlyle Credit Income Fund | 13G/A | 0.13% | Jan 31, 2024 | 2y |
| Chemung Canal Trust Company E.I. No. | CHMG Chemung Financial Corp | 13G/A | 7.04% | Dec 31, 2023 | 2y |
| Coliseum Capital Management, LLC | GIL Gildan Activewear Inc. | 13D/A | 5.9% | Apr 22, 2024 | 2y |
| GAMCO INVESTORS, INC. ET AL | MLI Mueller Industries Inc | 13D/A | 3.14% | Apr 22, 2024 | 2y |
| Saba Capital Management, L.P. | SBI Western Asset Intermediate Muni Fund Inc. | 13D/A | 4.79% | Apr 19, 2024 | 2y |
| BAKER BROS. ADVISORS LP | TCRX TScan Therapeutics, Inc. | 13D/A | 6.1% | Apr 19, 2024 | 2y |
| Findell Capital Partners LP | OPRT Oportun Financial Corp | 13D/A | 8.5% | Apr 19, 2024 | 2y |
| AIMS Asset Management Sdn Bhd | USAU U.S. Gold Corp. | 13G/A | 8.1% | Apr 19, 2024 | 2y |
| MILLENNIUM MANAGEMENT LLC | SMTC Semtech Corp | 13G | 5.3% | Apr 17, 2024 | 2y |
| Blufire Capital Limited | FHLT Future Health ESG Corp. Common stock | 13D | 50.88% | Apr 17, 2024 | 2y |
| Divisadero Street Capital Management, LP | INGN Inogen Inc | 13G | 5.9% | Apr 17, 2024 | 2y |
| Rory Wallace | BNED Barnes & Noble Education, Inc. | 13D/A | 9.7% | Apr 16, 2024 | 2y |
| BROWN ADVISORY INC | BELFA Bel Fuse Inc | 13G | 6.7% | Mar 31, 2024 | 2y |
| Emerald Bioventures, LLC | AVTX Avalo Therapeutics, Inc. | 13G | 5.6% | Mar 27, 2024 | 2y |
| Avoro Capital Advisors LLC | SYRE Spyre Therapeutics, Inc. | 13G/A | 5.1% | Dec 31, 2023 | 2y |
| DNX III, LLC | PARA Parabolic Technologies, Inc. | 13G | 6.97% | Dec 14, 2023 | 2y |
| Ned L. Sherwood | BRN Barnwell Industries Inc | 13D/A | 29% | Apr 22, 2024 | 2y |